RNXT Stock Analysis: Buy, Sell, or Hold?
RNXT - RenovoRx, Inc. Common Stock
$1.04
0.08 (8.33%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Apr 01, 2026
Get Alerted When RNXT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RNXT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RNXT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RNXT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RNXT is currently trading at $1.04, which is considered slightly high relative to its 30-day fair value range of $0.89 to $1.06.
Technical Outlook: Technically, RNXT is in a strong downtrend. The price is approaching resistance at $1.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.56 (+479.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RNXT is in a strong downtrend. The price is approaching resistance at $1.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.56 (+479.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$0.89 -
$1.06
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.3%)
- BULLISH: Trading 479.4% below Wall St target ($5.56)
Fair Price Analysis
30-Day Fair Range
$0.89 -
$1.06
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.87
Resistance Level
$1.07
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-3.37
Wall Street Target
$5.56
(+479.4%)
Last updated: January 31, 2026 9:29 AM ET
Data refreshes hourly during market hours. Next update: 10:29 AM
Data refreshes hourly during market hours. Next update: 10:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNXT showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Shaun Bagai
BUY
5000 shares
2025-08-25
Shaun Bagai
BUY
5000 shares
2025-08-22
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$500 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$214 | 60 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$830 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$89 | 61 BUY |
Advanced RNXT Option Strategies
Professional options setups generated by AI based on today's RNXT price and gamma walls.
